Subtype-Specific Divergent Roles of Calpain-1 and Calpain-2 in Basal a Triple-Negative Breast Cancer

dc.contributor.author Uner, Goklem
dc.contributor.author Oztarhan, Gokhan
dc.contributor.author Kirmizibayrak, Petek Ballar
dc.date.accessioned 2025-11-25T15:10:10Z
dc.date.available 2025-11-25T15:10:10Z
dc.date.issued 2025
dc.description.abstract BackgroundCAPN-1 and CAPN-2, two ubiquitously expressed calpains, have been implicated in cancer progression, but their distinct roles in breast cancer remain poorly defined. This study aims to define the opposing roles of CAPN-1 and CAPN-2 in breast cancer progression, with a focus on their regulatory impact on cell proliferation. Since these calpains may have different functions in the mammary gland, we aimed to investigate the possible antagonistic roles of CAPN-1 and CAPN-2 in breast cancer progression, focusing on their expression patterns and functional impact on cell proliferation.Methods and resultsWe analyzed breast cancer cell lines using immunoblotting and real-time cellular assays, showing that HCC1937 cells exhibit an opposite expression pattern of CAPN-1 and CAPN-2 compared to non-cancerous breast cells. CAPN-1 promoted cancer cell survival and negatively regulated CAPN-2 at both the protein and mRNA levels, whereas CAPN-2 suppressed proliferation. Additionally, the calpain activator AG-08 triggered cell death through CAPN-2 but not CAPN-1. In silico analysis confirmed higher CAPN-1 and lower CAPN-2 expression levels in breast cancer samples compared to normal tissue.ConclusionsThese findings indicate that CAPN-1 and CAPN-2 may exert antagonistic roles in breast cancer, but importantly, this effect was restricted to HCC1937 cells, representing a basal A TNBC subtype. Validation in additional basal A models and patient-derived samples will be essential to confirm these results. Our study, therefore, provides preliminary, model-specific insights into calpain regulation in TNBC and suggests that future therapeutic strategies should carefully account for subtype heterogeneity. en_US
dc.description.sponsorship Ege University, Office of Scientific Research Projects; Pharmaceutical Sciences Research Centre (FABAL, Ege University, Faculty of Pharmacy) en_US
dc.description.sponsorship We thank the Pharmaceutical Sciences Research Centre (FABAL, Ege University, Faculty of Pharmacy) for equipment support. en_US
dc.identifier.doi 10.1186/s12860-025-00556-6
dc.identifier.issn 2661-8850
dc.identifier.scopus 2-s2.0-105019034768
dc.identifier.uri https://doi.org/10.1186/s12860-025-00556-6
dc.identifier.uri https://hdl.handle.net/11147/18643
dc.language.iso en en_US
dc.publisher BMC en_US
dc.relation.ispartof BMC Molecular and Cell Biology en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Breast Cancer en_US
dc.subject Calpain-1 en_US
dc.subject Calpain-2 en_US
dc.subject Proteases en_US
dc.subject Cancer Treatment en_US
dc.title Subtype-Specific Divergent Roles of Calpain-1 and Calpain-2 in Basal a Triple-Negative Breast Cancer
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 57219944322
gdc.author.scopusid 7003998497
gdc.author.scopusid 57222366085
gdc.author.wosid Bedir, Erdal/Abi-3895-2020
gdc.author.wosid Ballar Kirmizibayrak, Petek/Y-6869-2018
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Institute of Technology en_US
gdc.description.departmenttemp [Uner, Goklem; Bedir, Erdal] Izmir Inst Technol, Fac Engn, Dept Bioengn, TR-35430 Izmir, Turkiye; [Kirmizibayrak, Petek Ballar] Ege Univ, Fac Pharm, Dept Biochem, TR-35100 Izmir, Turkiye en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.volume 26 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q3
gdc.identifier.openalex W4415267523
gdc.identifier.pmid 41102637
gdc.identifier.wos WOS:001595360200001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.openalex.collaboration National
gdc.openalex.fwci 0.0
gdc.openalex.normalizedpercentile 0.41
gdc.opencitations.count 0
gdc.plumx.scopuscites 0
gdc.scopus.citedcount 0
gdc.wos.citedcount 0
relation.isAuthorOfPublication.latestForDiscovery 461a570d-2493-4349-b634-a876ced8cd22
relation.isOrgUnitOfPublication.latestForDiscovery 9af2b05f-28ac-4003-8abe-a4dfe192da5e

Files